DE69918690D1 - Stabile igf/igfbp pharmazeutische formulierungen - Google Patents

Stabile igf/igfbp pharmazeutische formulierungen

Info

Publication number
DE69918690D1
DE69918690D1 DE69918690T DE69918690T DE69918690D1 DE 69918690 D1 DE69918690 D1 DE 69918690D1 DE 69918690 T DE69918690 T DE 69918690T DE 69918690 T DE69918690 T DE 69918690T DE 69918690 D1 DE69918690 D1 DE 69918690D1
Authority
DE
Germany
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
stable igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918690T
Other languages
English (en)
Other versions
DE69918690T2 (de
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69918690D1 publication Critical patent/DE69918690D1/de
Publication of DE69918690T2 publication Critical patent/DE69918690T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69918690T 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen Expired - Lifetime DE69918690T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89062 1979-10-29
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (2)

Publication Number Publication Date
DE69918690D1 true DE69918690D1 (de) 2004-08-19
DE69918690T2 DE69918690T2 (de) 2005-08-18

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918690T Expired - Lifetime DE69918690T2 (de) 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen

Country Status (14)

Country Link
US (2) US6436897B2 (de)
EP (1) EP1082133B1 (de)
JP (1) JP2002516871A (de)
KR (1) KR20010052500A (de)
CN (1) CN1201816C (de)
AT (1) ATE270898T1 (de)
AU (1) AU4326799A (de)
BR (1) BR9910863A (de)
CA (1) CA2330925C (de)
DE (1) DE69918690T2 (de)
ES (1) ES2221456T3 (de)
HK (1) HK1040637B (de)
IL (1) IL139969A0 (de)
WO (1) WO1999062536A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
WO2006023665A2 (en) 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
US7968679B2 (en) * 2004-12-24 2011-06-28 Insmed Incorporated Purified rhIGF-I/rhIGFBP-3 complexes and their method of manufacture
PE20060958A1 (es) * 2005-01-25 2006-10-27 Wyeth Res Ireland Ltd Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
WO2010096125A1 (en) * 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
NZ600454A (en) 2009-11-30 2014-10-31 Univ Queensland Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
US11035764B2 (en) * 2012-02-03 2021-06-15 Charm Sciences, Inc. Extraction of mycotoxins
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
US20180188139A1 (en) * 2015-06-22 2018-07-05 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
HRP20231379T1 (hr) 2015-12-03 2024-02-16 Regeneron Pharmaceuticals, Inc. Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
EP3397644A4 (de) * 2015-12-31 2018-12-19 Siemens Healthcare Diagnostics Inc. Nicht-rekombinantes humanes insulin-like-wachstumsfaktorbindendes proteinkonzentrat
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018068012A1 (en) 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
SMT202500093T1 (it) * 2020-10-19 2025-03-12 Oak Hill Bio Ltd Composizioni adatte all'uso nei neonati
EP4469806A1 (de) * 2022-01-24 2024-12-04 Oak Hill Bio Limited Lot-freisetzungstests für igf?1/igfbp-komplexe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE226958T1 (de) 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
ATE225666T1 (de) * 1993-11-15 2002-10-15 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
WO1995013823A1 (en) 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
CN1201816C (zh) 2005-05-18
WO1999062536A2 (en) 1999-12-09
HK1040637B (zh) 2006-01-06
ES2221456T3 (es) 2004-12-16
CA2330925A1 (en) 1999-12-09
DE69918690T2 (de) 2005-08-18
WO1999062536A3 (en) 2000-03-30
KR20010052500A (ko) 2001-06-25
US20030087806A1 (en) 2003-05-08
CN1315868A (zh) 2001-10-03
HK1040637A1 (en) 2002-06-21
EP1082133A2 (de) 2001-03-14
US6436897B2 (en) 2002-08-20
AU4326799A (en) 1999-12-20
BR9910863A (pt) 2002-06-11
ATE270898T1 (de) 2004-07-15
EP1082133B1 (de) 2004-07-14
US20020004478A1 (en) 2002-01-10
CA2330925C (en) 2010-02-09
IL139969A0 (en) 2002-02-10
JP2002516871A (ja) 2002-06-11

Similar Documents

Publication Publication Date Title
ATE270898T1 (de) Stabile igf/igfbp pharmazeutische formulierungen
ID27600A (id) KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
PT1058558E (pt) Vacinas vivas recombinantes administradas com adjuvante
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
PT2193809E (pt) Formulações de fator viii livres de albumina
DE69819481D1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
NO20020526D0 (no) Moksifloksasinformulering med koksalt
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DK1131331T3 (da) 13-leddede azalider og deres anvendelse som antibiotiske midler
SE9702680D0 (sv) New formulation
EE04954B1 (et) Peroraalselt v?i paikselt manustatav farmatseutiline preparaat ja selle ravimvorm
NZ511445A (en) Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
SE9604795D0 (sv) New pharmaceutical formulation
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
FI933719L (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
AR034749A1 (es) Formulaciones de interferon beta humano
DK0482108T3 (da) Substituerede 2-imidazoliner samt fremstilling og anvendelse deraf
DE69703308D1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
TR200003521T2 (tr) Yeniden-kombine-edilen insan interferonu beta-1a (IFN-beta-1a) formülasyonu.
ES2131482A1 (es) Formulacion acuosa de bambuterol.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition